Poor prognosis of <i>KRAS</i> or <i>BRAF</i> mutant colorectal liver metastasis without microsatellite instability
Yuzo Umeda(Okayama University), Toshiyoshi Fujiwara(Okayama University), Masashi Utsumi(Okayama University), Daisuke Nobuoka(Fukuyama City Hospital), Takeshi Nagasaka(Okayama University), Susumu Shinoura(Okayama University), Kazuhiro Yoshida(Nagasaki University), Yoshiko Mori(Okayama University), Dongsheng Sun(University of Maryland, Baltimore), Takahito Yagi(Okayama University), Hiroshi Sadamori(Okayama University), Ryuich Yoshida(Okayama University), Daisuke Satoh(Okayama University)
Cited by 61
Related Papers
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment
|Molecular Cancer Therapeutics|2021|258
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
|OncoImmunology|2016|178